Certified by Founder Lodge
LoQus23 Therapeutics Ltd
United Kingdom - Cambridge, Cambridgeshire
START UP
1 Disclosed Funding Rounds $46,550,175
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| October, 02 ,2024 | Series A | $46,550,175 |
SV Health Investors
Forbion
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Navier AI | $6,500,000 | (Dec 17, 2025)
Auxira Health | $7,800,000 | (Dec 17, 2025)
AIR Platforms | $6,100,000 | (Dec 17, 2025)
OnCorps AI | $55,000,000 | (Dec 12, 2025)
